Oct 5, 2024, 08:59
Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million
Palvella Therapeutics shared on LinkedIn:
“Today, we announced Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million which will support the advancement of our ongoing Phase 3 single-arm baseline-controlled trial in microcystic lymphatic malformations.
This underscores our belief in the potential of QTORIN™ rapamycin which has also received FDA Breakthrough Therapy, Fast Track, and Orphan Designations for this serious, rare and chronically debilitating genetic disease.
Learn more here.”
Source: Palvella Therapeutics/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12